Michael Barbella, Managing Editor03.08.24
Neuronetics Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NeuroSite Coil Placement Accessory, a tool that simplifies measurement and coil positioning during NeuroStar transcranial magnetic stimulation (TMS) treatments. This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.
“The NeuroSite FDA clearance is the latest of many enhancements designed to improve the patient experience, exemplifying our ongoing commitment to continually advance medical technology for mental health,” stated Cory Anderson, senior vice president of R&D and Clinical. “We are thrilled to introduce yet another innovative accessory to our suite of products that deliver a fast, easy, reliable treatment that both patients and providers trust.”
By leveraging the patient's unique anatomical features, NeuroSite Coil Placement Accessory ensures precise and reproducible coil placement. This streamlines the NeuroStar TMS process with significantly fewer patient setup steps1, thereby improving efficiency for providers’ offices and improving the patient experience while maintaining the accuracy established by the current NeuroStar Head Support System (HSS).
“As a NeuroStar TMS provider with multiple systems, I appreciate how user-friendly NeuroSite is, along with the flexibility it brings to patient positioning across all generations of NeuroStar devices,” said Dr. Kenneth Pages, medical director at TMS of South Tampa, Fla. “This latest tool reinforces my confidence in providing consistent results and exceptional care to my patients.”
Neuronetics Inc. is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with more than 5.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry.
“The NeuroSite FDA clearance is the latest of many enhancements designed to improve the patient experience, exemplifying our ongoing commitment to continually advance medical technology for mental health,” stated Cory Anderson, senior vice president of R&D and Clinical. “We are thrilled to introduce yet another innovative accessory to our suite of products that deliver a fast, easy, reliable treatment that both patients and providers trust.”
By leveraging the patient's unique anatomical features, NeuroSite Coil Placement Accessory ensures precise and reproducible coil placement. This streamlines the NeuroStar TMS process with significantly fewer patient setup steps1, thereby improving efficiency for providers’ offices and improving the patient experience while maintaining the accuracy established by the current NeuroStar Head Support System (HSS).
“As a NeuroStar TMS provider with multiple systems, I appreciate how user-friendly NeuroSite is, along with the flexibility it brings to patient positioning across all generations of NeuroStar devices,” said Dr. Kenneth Pages, medical director at TMS of South Tampa, Fla. “This latest tool reinforces my confidence in providing consistent results and exceptional care to my patients.”
Neuronetics Inc. is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with more than 5.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry.